Danish healthcare company Novo Nordisk has dropped prices for its weight-loss and diabetes drug Wegoy, the injectable semaglutide, by as much as 37 per cent for its starting dose strength. The development comes on the heels of its India-partnership with Emcure Pharmaceuticals to get Wegovy to more patients across the country.

Wegovy was launched in June as a once-weekly innovative device in five dose strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg & 2.4 mg.

The starting dose of Wegovy (0.25 mg) will now be available at a weekly price of ₹2,712, the company said, reflecting a 37 per cent price drop. Prices are down 20 per cent on dose strengths of 0.5 mg and 1.0 mg; down 32 per cent on 1.7 mg; and 36.9 per cent on the highest dose strength of 2.4 mg.

Vikrant Shrotriya, Managing Director, Novo

See Full Page